Chengdu Duote Antibody Pharmaceutical Co. Ltd. has described antibody-drug conjugates comprising antibody or antigen-binding fragments covalently linked to eribulin derivatives through a linker reported to be useful for the treatment of cancer.
Nanjing Mingde New Drug Research Co. Ltd. has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding agent coupled to an estrogen receptor α (ER-α; ESR1)-targeting moiety via linker. They are reported to be useful for the treatment of breast cancer.
Shenzhen Zhongge Biotechnology Co. Ltd. has identified interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors and derived PROTAC compounds reported to be useful for the treatment of autoimmune disorders, inflammatory disorders, cancer, transplant rejection and more.
Beijing Zheyuan Technology Co. Ltd. has synthesized serine/threonine-protein kinase PLK1 (STPK13) inhibitors reported to be useful for the treatment of cancer and sepsis.
Alzheimer’s disease (AD) is characterized by synaptic damage, neuronal loss and cognitive decline caused by the neurotoxic effects of amyloid-β. It is the third most significant challenge to global health nowadays and currently available drugs have limited efficacy.
Adcendo ApS and Multitude Therapeutics Inc. have signed a licensing agreement for the development of a highly differentiated antibody-drug conjugate (ADC) targeting tissue factor, designated ADCE-T02.
RNA Therapeutics Inc. has received a written response from the FDA to its pre-IND application questions regarding the development of its lead asset, RNAT-89 (BLA-761423), an mRNA LNP formulation to express darbepoetin.
Thyroid hormones are involved in growth, development and metabolism processes. The thyroid hormone receptor β (THRβ) isoform, mainly expressed in the liver, is responsible for the reduction of cholesterol levels and thus is considered a therapeutic target for the treatment of dyslipidemia, obesity and related disorders.
Cumulus Oncology Ltd. has announced key milestones, in partnership with collaborator Leadxpro AG, in the companies’ protein structure-driven GPR68 drug discovery project.